Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Dharan NJ, Cooper DA. Long-term durability of HIV viral load suppression. Lancet HIV 2017;4:e279-e280. [PMID: 28479491 DOI: 10.1016/s2352-3018(17)30063-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Accepted: 03/20/2017] [Indexed: 01/17/2023]

For:	Dharan NJ, Cooper DA. Long-term durability of HIV viral load suppression. Lancet HIV 2017;4:e279-e280. [PMID: 28479491 DOI: 10.1016/s2352-3018(17)30063-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Accepted: 03/20/2017] [Indexed: 01/17/2023]

Number

Cited by Other Article(s)

Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Crain CR, Traunbauer AK, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Dorazio D, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Sieg S, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZ. Viral and host mediators of non-suppressible HIV-1 viremia. Nat Med 2023;29:3212-3223. [PMID: 37957382 PMCID: PMC10719098 DOI: 10.1038/s41591-023-02611-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 09/25/2023] [Indexed: 11/15/2023]

Affiliation(s)

Abbas Mohammadi Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Valley Health System, Las Vegas, NV, USA
Behzad Etemad Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Xin Zhang Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Beijing Friendship Hospital Pinggu Campus, Capital Medical University, Beijing, China
Yijia Li Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA University of Pittsburgh, Pittsburgh, PA, USA
Gregory J Bedwell Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Radwa Sharaf Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Autumn Kittilson Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Meghan Melberg Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Charles R Crain Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
Anna K Traunbauer Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
Colline Wong Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Jesse Fajnzylber Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Daniel P Worrall Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
Alex Rosenthal Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Hannah Jordan Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Nikolaus Jilg Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Clarety Kaseke Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
Francoise Giguel Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Xiaodong Lian Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
Rinki Deo Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Elisabeth Gillespie Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Rida Chishti Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Sara Abrha Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Taylor Adams Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Abigail Siagian Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Dominic Dorazio Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Peter L Anderson Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Steven G Deeks Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
Michael M Lederman Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Sigal Yawetz Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Daniel R Kuritzkes Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Mathias D Lichterfeld Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
Scott Sieg Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Athe Tsibris Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Mary Carrington Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Zabrina L Brumme Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
Jose R Castillo-Mancilla Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Alan N Engelman Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Gaurav D Gaiha Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
Jonathan Z Li Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Collapse

Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZ. Viral and Host Mediators of Non-Suppressible HIV-1 Viremia. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2023:2023.03.30.23287124. [PMID: 37034605 PMCID: PMC10081408 DOI: 10.1101/2023.03.30.23287124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]

Affiliation(s)

Abbas Mohammadi Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Behzad Etemad Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Xin Zhang Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Yijia Li University of Pittsburgh, Pittsburgh, PA, USA
Gregory J. Bedwell Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Radwa Sharaf Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Autumn Kittilson Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Meghan Melberg Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Colline Wong Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Jesse Fajnzylber Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Daniel P. Worrall Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
Alex Rosenthal Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Hannah Jordan Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Nikolaus Jilg Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Clarety Kaseke Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
Francoise Giguel Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Xiaodong Lian Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
Rinki Deo Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Elisabeth Gillespie Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Rida Chishti Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Sara Abrha Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Taylor Adams Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Abigail Siagian Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Peter L. Anderson Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
Steven G. Deeks Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA
Michael M. Lederman Center for AIDS Research, Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Sigal Yawetz Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Daniel R. Kuritzkes Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Mathias D. Lichterfeld Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
Athe Tsibris Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Mary Carrington Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Zabrina L. Brumme Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
Jose R. Castillo-Mancilla Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
Alan N. Engelman Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Gaurav D. Gaiha Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
Jonathan Z. Li Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Collapse

Ntlantsana V, Hift RJ, Mphatswe WP. HIV viraemia during pregnancy in women receiving preconception antiretroviral therapy in KwaDukuza, KwaZulu-Natal. South Afr J HIV Med 2019;20:847. [PMID: 31061722 PMCID: PMC6494933 DOI: 10.4102/sajhivmed.v20i1.847] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 02/05/2019] [Indexed: 01/01/2023] Open

Abstract

BACKGROUND

Preconception antiretroviral therapy (PCART) followed by sustained viral suppression is effective in preventing mother-to-child transmission of HIV. The rates of persistent and transient viraemia in such patients have not been prospectively assessed in South Africa.

OBJECTIVES

We determined the prevalence of transient and persistent viraemia in HIV-positive women entering antenatal care on PCART and studied variables associated with viraemia.

METHODS

We performed a prospective cross-sectional observational study of HIV-positive pregnant women presenting to a primary healthcare facility in KwaZulu-Natal. All had received at least 6 months of first-line PCART. Viral load (VL) was measured, patients were interviewed, adherence estimated using a visual analogue scale and adherence counselling provided. Viral load was repeated after 4 weeks where baseline VL exceeded 50 copies/mL.

RESULTS

We enrolled 82 participants. Of them, 59 (72%) pregnancies were unplanned. Fifteen participants (18.3%) were viraemic at presentation with VL > 50 copies/mL. Of these, seven (8.5%) had viral suppression (VL < 50 copies/mL), and eight remained viraemic at the second visit. Adherence correlated significantly with viraemia at baseline. Level of knowledge correlated with adherence but not with lack of viral suppression at baseline. Socio-economic indicators did not correlate with viraemia. No instances of vertical transmission were observed at birth.

CONCLUSIONS

Approximately 20% of women receiving PCART may demonstrate viraemia. Half of these may be transient. Poor adherence is associated with viraemia, and efforts to encourage and monitor adherence are essential. The rate of unplanned pregnancies is high, and antiretroviral therapy programmes should focus on family planning needs of women in the reproductive age group to prevent viral non-suppression prior to pregnancy.

KEYWORDS

Preconception Antiretroviral Therapy; HIV; Viraemia; Antenatal Care; Adherence.

Collapse

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1. AIDS 2019;33:745-751. [PMID: 30829745 PMCID: PMC6410964 DOI: 10.1097/qad.0000000000002126] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Abstract

Objectives:

Evaluate long-term rates of virological failure and treatment interruption for people living with HIV (PLWHIV) with viral suppression on first-line efavirenz + tenofovir disoproxil fumarate + emtricitabine/lamivudine (EFV + TDF + FTC/3TC), and compare these according to patient characteristics.

Methods:

PLWHIV enrolled in the Collaboration of Observational HIV Epidemiological Research Europe cohort collaboration, who started first-line EFV + TDF + FTC/3TC at age at least 16 years and had viral suppression (<200 copies/ml) within 9 months were included. Rates of virological failure (≥200 copies/ml) and (complete) treatment interruption were estimated according to years since initial suppression. We used Poisson regression to examine associations of baseline characteristics with rates of virological failure or treatment interruption.

Results:

Among 19 527 eligible PLWHIV with median (interquartile range) follow-up 3.7 (2.0–5.6) years after initial viral suppression, the estimated rate of the combined incidence of virological failure or treatment interruption fell from 9.0/100 person-years in the first year to less than 4/100 person-years beyond 3 years from suppression; considering only those remaining on EFV + TDF + FTC/3TC, the combined rate dropped from 8.2/100 person-years in the first year to less than 3.5/100 person-years beyond 3 years. PLWHIV with injecting drug-related or heterosexual transmission were at higher risk of virological failure or treatment interruption, as were those of Black ethnicity. PLWHIV aged less than 35 years were at higher risk of virological failure and treatment interruption.

Conclusion:

PLWHIV starting first-line EFV + TDF + FTC/3TC had low rates of virological failure and treatment interruption up to 10 years from initial suppression. Demographic characteristics can be used to identify subpopulations with higher risks of these outcomes.

Collapse

Benítez-Gutiérrez L, Soriano V, Requena S, Arias A, Barreiro P, de Mendoza C. Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Rev Clin Pharmacol 2018;11:507-517. [PMID: 29595351 DOI: 10.1080/17512433.2018.1453805] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]